Atlas Trials

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Clinical trial NCT02961101 · RECRUITING

Trial details

NCT number
NCT02961101
Sponsor
Han weidong
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Malignancies Multiple
Start date
2016-05-01
Primary completion
2026-05-01
Enrollment
250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.